# Phase 3 Small Cell Lung Carcinoma trials: 31 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 31 trials in phase 3 for Small Cell Lung Carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Small Cell Lung Carcinoma trials: 31 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/small-cell-lung-carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 31
- Recruiting or not yet: 31
- Read on: November 19, 2026

## Trials

The 25 newest of 31, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947121 | A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer... | GlaxoSmithKline | Phase 3 | Not yet recruiting | Lung Neoplasm | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947121) |
| November 2, 2026 | NCT07908537 | A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004) | Merck Sharp & Dohme LLC | Phase 3 | Not yet recruiting | Small Cell Lung Cancer | 564 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908537) |
| September 3, 2026 | NCT07802821 | A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih... | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Extensive-stage Small Cell Lung Cancer | 556 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802821) |
| August 31, 2026 | NCT07796100 | A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint... | Zai Lab (Shanghai) Co., Ltd. | Phase 3 | Not yet recruiting | Extensive-Stage Small Cell Lung Cancer | 530 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796100) |
| August 21, 2026 | NCT07778316 | Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) | Amgen | Phase 3 | Recruiting | Small Cell Lung Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778316) |
| July 27, 2026 | NCT07728955 | A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as... | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | Not yet recruiting | Small Cell Lung Cancer ( SCLC ) | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07728955) |
| June 9, 2026 | NCT07637513 | Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer | PrECOG, LLC. | Phase 3 | Not yet recruiting | Limited Stage Small-Cell Lung Cancer | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07637513) |
| June 4, 2026 | NCT07625644 | BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) | SystImmune Inc. | Phase 3 | Recruiting | Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung... | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625644) |
| March 30, 2026 | NCT07502300 | A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Extensive-stage Small-cell Lung Cancer | 562 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502300) |
| March 16, 2026 | NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and... | Boehringer Ingelheim | Phase 3 | Recruiting | Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 670 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472517) |
| January 26, 2026 | NCT07365241 | A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants... | AbbVie | Phase 3 | Recruiting | Small Cell Lung Cancer | 531 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07365241) |
| October 20, 2025 | NCT07218146 | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | Zai Lab (Shanghai) Co., Ltd. | Phase 3 | Recruiting | Small-cell Lung Cancer | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07218146) |
| September 24, 2025 | NCT07189455 | Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 | Recruiting | Small-cell Lung Cancer | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189455) |
| August 1, 2025 | NCT07099898 | A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) \[EMBOLD SCLC-301\] | GlaxoSmithKline | Phase 3 | Recruiting | Neoplasms, Lung | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07099898) |
| June 11, 2025 | NCT07015892 | Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial | Instituto de Investigación Biomédica de Salamanca | Phase 3 | Recruiting | Small Cell Lung Carcinoma | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07015892) |
| June 8, 2025 | NCT07010263 | A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following... | Akeso | Phase 3 | Recruiting | Small Cell Lung Cancer | 560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07010263) |
| May 7, 2025 | NCT06961201 | Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell... | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Extensive-stage Small Cell Lung Cancer (ES-SCLC), The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic... | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06961201) |
| May 1, 2025 | NCT06954246 | A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Small Cell Lung Cancer Extensive Stage | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06954246) |
| February 21, 2025 | NCT06840704 | Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer | Hunan Cancer Hospital | Phase 3 | Recruiting | Non Small Cell Lung Cancer, Small Cell Lung Cancer | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06840704) |
| January 23, 2025 | NCT06789796 | a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Small-cell Lung Cancer | 636 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06789796) |
| December 5, 2024 | NCT06719336 | Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001) | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Extensive-stage Small Cell Lung Cancer | 182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06719336) |
| December 2, 2024 | NCT06712355 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung... | BioNTech SE | Phase 3 | Recruiting | Extensive-stage Small-cell Lung Cancer | 621 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06712355) |
| October 17, 2024 | NCT06646276 | A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin... | Bristol-Myers Squibb | Phase 3 | Recruiting | Extensive-Stage Small Cell Lung Cancer | 530 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06646276) |
| September 3, 2024 | NCT06581380 | JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer | JenKem Technology Co., Ltd. | Phase 3 | Not yet recruiting | Small Cell Lung Cancer | 394 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06581380) |
| July 30, 2024 | NCT06526624 | A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer | Hansoh BioMedical R&D Company | Phase 3 | Not yet recruiting | Limited-stage Small-cell Lung Cancer | 406 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06526624) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 3 |
| [Luye Pharma Group Ltd.](https://specstream.ai/data/clinical-trials/company/luye-pharma-group-ltd) | 2 |
| [Zai Lab (Shanghai) Co., Ltd.](https://specstream.ai/data/clinical-trials/company/zai-lab-shanghai-co-ltd) | 2 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 2 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| PrECOG, LLC. | 1 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 1 |
| Advenchen Laboratories Nanjing Ltd. | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 1 |
| [BioNTech SE](https://specstream.ai/data/clinical-trials/company/biontech-se) | 1 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 1 |
| SystImmune Inc. | 1 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 1 |
| [Changchun GeneScience Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/changchun-genescience-pharmaceutical-co-ltd) | 1 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 1 |
| [Suzhou Zelgen Biopharmaceuticals Co.,Ltd](https://specstream.ai/data/clinical-trials/company/suzhou-zelgen-biopharmaceuticals-co-ltd) | 1 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 1 |
| Shanghai Junshi Bioscience Co., Ltd. | 1 |
| Instituto de Investigación Biomédica de Salamanca | 1 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 1 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 1 |
| Hunan Cancer Hospital | 1 |
| JenKem Technology Co., Ltd. | 1 |
| [Hansoh BioMedical R&D Company](https://specstream.ai/data/clinical-trials/company/hansoh-biomedical-r-and-d-company) | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 18 |
| Spain | 10 |
| United States | 9 |
| Japan | 8 |
| France | 8 |
| Germany | 8 |
| Australia | 7 |
| Greece | 7 |
| Italy | 7 |
| Poland | 7 |
| Turkey (Türkiye) | 7 |
| Switzerland | 6 |
| South Korea | 6 |
| Netherlands | 6 |
| Brazil | 5 |
| Canada | 5 |
| Romania | 5 |
| United Kingdom | 5 |
| Austria | 5 |
| Belgium | 5 |
| Czechia | 5 |
| Hungary | 4 |
| Argentina | 3 |
| Bulgaria | 3 |
| Mexico | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Construction management firms in the United States](https://specstream.ai/data/businesses/construction-management-firms/united-states)
- [Pediatric neurology practices in the United States](https://specstream.ai/data/businesses/pediatric-neurology-practices/united-states)
- [British restaurants in the United States](https://specstream.ai/data/businesses/british-restaurants/united-states)
- [Mediterranean restaurants in the United States](https://specstream.ai/data/businesses/mediterranean-restaurants/united-states)
- [Awning suppliers in the United States](https://specstream.ai/data/businesses/awning-suppliers/united-states)
- [IP and internet law firms in the United States](https://specstream.ai/data/businesses/ip-and-internet-law-firms/united-states)
